<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03231670</url>
  </required_header>
  <id_info>
    <org_study_id>RT-12</org_study_id>
    <nct_id>NCT03231670</nct_id>
  </id_info>
  <brief_title>Innate Immune Response of Blood Cells in Patients With Pneumonia</brief_title>
  <acronym>ASTRAL</acronym>
  <official_title>Analysis of Blood Cells Innate Immune Response in Patients With Lobar Pneumonia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lille Catholic University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut Pasteur de Lille</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Lille Catholic University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pulmonary bacterial infections such as exacerbations of chronic bronchitis, nosocomial and&#xD;
      community-acquired pneumonia represent a major public health issue. Antibiotics have shown&#xD;
      their efficacy by direct antimicrobial activity and their limit particularly in case of&#xD;
      multidrug-resistant microorganisms or in treating patients with aggravating pathologies.&#xD;
      Innate immunity could be an alternative or complementary therapeutic pathway. Innate immunity&#xD;
      receptors bind universal and invariant microbial molecular patterns present in bacteria,&#xD;
      virus, fungus or parasite. Toll-like Receptors (TLR) activation by microbial agonist&#xD;
      stimulates the innate immunity response which results in the production of chemokines,&#xD;
      cytokines, antimicrobial molecules and the recruitment of innate cells.&#xD;
&#xD;
      The &quot; Pulmonary Infection and Innate Immunity &quot; team of the Immunity and Infection Center in&#xD;
      Lille (Group of Dr. Sirard and Carnoy) has a long expertise in the study of TLR5 and its&#xD;
      agonist, the flagellin, a structural protein of bacterial flagella. TLR5 is expressed on the&#xD;
      cell surface of macrophages, monocytes, dendritic and epithelial cells. Several studies in&#xD;
      mice have shown the flagellin prophylactic potential during bacterial infections through a&#xD;
      TLR5 dependent stimulation of innate immunity. Recently, the group of Dr. Sirard and Carnoy&#xD;
      has shown that flagellin can be used in association with antibiotics to treat Streptococcus&#xD;
      pneumoniae respiratory infections in mice. The results demonstrate that an agonist of TLR can&#xD;
      increase the therapeutic index of an antibiotic and improve the pulmonary anti-infectious&#xD;
      reaction. This innovative approach allows us to consider new antibacterial strategies where&#xD;
      antibiotics have reached their limit (nosocomial infection, multidrug-resistant bacteria…).&#xD;
      TLR agonists can activate multiple human cell type. Indeed, blood cells activation by TLR&#xD;
      agonists have been recently characterized in healthy volunteers.&#xD;
&#xD;
      However, there is no available data on the ability of TLR agonists to activate cells from&#xD;
      patients with infectious pneumopathies. A study in these patients is inevitable if one is to&#xD;
      consider the therapeutic use of agonists in respiratory pathologies.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">October 13, 2017</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in IL-6 specific transcripts</measure>
    <time_frame>Baseline and 2 months</time_frame>
    <description>IL-6 specific transcripts will be measured in blood mononuclear cells after stimulation with a TLR5 agonist.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in expression of innate immunity genes after stimulation by TLR2 agonist</measure>
    <time_frame>Baseline and 2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in expression of innate immunity genes after stimulation by TLR4 agonist</measure>
    <time_frame>Baseline and 2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in expression of innate immunity genes after stimulation by TLR5 agonist</measure>
    <time_frame>Baseline and 2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in expression of innate immunity genes after stimulation by TLR9 agonist</measure>
    <time_frame>Baseline and 2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in ELISA assay on mediators of inflammation with stimulation by TRL2 agonist</measure>
    <time_frame>Baseline and 2 months</time_frame>
    <description>ELISA assay on mediators of inflammation in the supernatant of blood mononuclear cells stimulated by TRL2 agonist</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in ELISA assay on mediators of inflammation with stimulation by TRL4 agonist</measure>
    <time_frame>Baseline and 2 months</time_frame>
    <description>ELISA assay on mediators of inflammation in the supernatant of blood mononuclear cells stimulated by TRL4 agonist</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in ELISA assay on mediators of inflammation with stimulation by TRL5 agonist</measure>
    <time_frame>Baseline and 2 months</time_frame>
    <description>ELISA assay on mediators of inflammation in the supernatant of blood mononuclear cells stimulated by TRL5 agonist</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in ELISA assay on mediators of inflammation with stimulation by TRL9 agonist</measure>
    <time_frame>Baseline and 2 months</time_frame>
    <description>ELISA assay on mediators of inflammation in the supernatant of blood mononuclear cells stimulated by TRL9 agonist</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Genotyping of TLR 2 gene</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Genotyping of TLR 4 gene</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Genotyping of TLR 5 gene</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Genotyping of TLR 9 gene</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">38</enrollment>
  <condition>Lobar Pneumonia</condition>
  <arm_group>
    <arm_group_label>lobar pneumonia</arm_group_label>
    <description>Inpatient with lobar pneumonia will undergo a blood sampling during their hospitalization and after resolution of the infection (2 Months)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood sampling</intervention_name>
    <description>5ml blood will be taken in addition to standard sampling</description>
    <arm_group_label>lobar pneumonia</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples 5ml&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patient hospitalized in the department of pneumology for whom clinical, radiological&#xD;
        and biological criteria confirm the diagnosis of lobar pneumonia&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patient hospitalized in the department of pneumology for whom clinical,&#xD;
             radiological and biological criteria confirm the diagnosis of lobar pneumonia&#xD;
&#xD;
          -  Beneficiary of the French National Health Insurance Fund&#xD;
&#xD;
          -  Signed informed consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient under guardianship&#xD;
&#xD;
          -  Patient with acute respiratory distress syndrome or septic shock&#xD;
&#xD;
          -  Pregnant women&#xD;
&#xD;
          -  Patient with HIV, HCV or Mycobacterium tuberculosis&#xD;
&#xD;
          -  Transplanted patient receiving immunosuppressive therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christophe Carnoy, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Institut Pasteur de Lille</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean-Claude Sirard, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Institut Pasteur de Lille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amélie Lansiaux, MD, PhD</last_name>
    <phone>03 20 22 52 69</phone>
    <phone_ext>+33</phone_ext>
    <email>lansiaux.amelie@ghicl.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jean-Jacques Vitagliano, PhD</last_name>
    <phone>03 20 22 57 51</phone>
    <email>vitagliano.jean-jacques@ghicl.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hôpital Saint-Philibert</name>
      <address>
        <city>Lomme</city>
        <state>Hauts De France</state>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne-France Georgel</last_name>
    </contact>
    <investigator>
      <last_name>Philippe Delecluse, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nicolas Masson, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>July 24, 2017</study_first_submitted>
  <study_first_submitted_qc>July 26, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 27, 2017</study_first_posted>
  <last_update_submitted>August 20, 2018</last_update_submitted>
  <last_update_submitted_qc>August 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

